Microarray pathway analysis comparing baricitinib and adalimumab in moderate to severe rheumatoid arthritis patients, from a Phase 3 study
المؤلفون الرئيسيون: | Emery, P, Taylor, P, Weinblatt, M, Tanaka, Y, Keystone, E, Dow, E, Higgs, R, Macias, W, Rocha, G, Rooney, T, Schlichting, D, Zuckerman, S, McInnes, I |
---|---|
التنسيق: | Conference item |
اللغة: | English |
منشور في: |
Wiley
2017
|
مواد مشابهة
-
Baricitinib versus placebo or adalimumab in rheumatoid arthritis
حسب: Taylor, P, وآخرون
منشور في: (2017) -
Characterization and changes of lymphocyte subsets in baricitinib-treated patients with rheumatoid arthritis: an integrated analysis
حسب: Tanaka, Y, وآخرون
منشور في: (2018) -
Efficacy and safety of switching from adalimumab to baricitinib: Phase 3 data in patients with rheumatoid arthritis
حسب: Taylor, P, وآخرون
منشور في: (2016) -
Efficacy and safety of switching from adalimumab to baricitinib: phase 3 data in patients with rheumatoid arthritis
حسب: Taylor, P, وآخرون
منشور في: (2017) -
Efficacy and safety of switching from adalimumab to baricitinib: long-term data from phase 3 extension study in patients with rheumatoid arthritis
حسب: Weinblatt, M, وآخرون
منشور في: (2018)